Halozyme Therapeutics Stock Price (NASDAQ:HALO)

Add to My Stocks
$12.27 $0.23 (1.91%) HALO stock closing price Feb 24, 2017 (Closing)
Halozyme Therapeutics
24 FEB 2017
amigobulls logo
HALO hand_up
HALO vs S&P 500
Closing Price: Feb 24, 2017
$12.27 ( 1.91%)
S&P 500
2367.3 ( 0.15%)
52 Week Price Range
1 Year Return: 54.16%
Q3 Growth*
Profitable ?
net image
2016 Q3 Net Loss
home image
☆ ☆ ☆ ☆ ☆★ ★ ★ ★ ★
Double Tap To Exit Full Screen

Halozyme Therapeutics Snapshot Video

13 5 2

HALO Stock Details

Prev Close* : $12.04
Market Cap:
Day Low: $11.82
52 Week Low: $7.52
Open: $11.84
Volume: 1253648
Day High: $12.27
52 Week High: $14.38

Latest Stock Market News

Latest Articles

Halozyme Therapeutics News - From Partners

Company News for January 06, 2017   by Zacks on Jan 06, 2017

HALO Stockcharts

View HALO PE ratio, PS ratio stocks charts and compare with peers.
HALO Chart
Note: Compare Halozyme Therapeutics stock price history with the index and industry peers.

Halozyme Therapeutics Valuation

PS ratio (
price to sales ratio
PB ratio (
price to book ratio

Halozyme Therapeutics Financial Ratios

Asset Turnover
Receivables Turnover

HALO Industry Peers

Company Price Change (%)
Dbv Tech (DBVT)35.780.39 (1.08%)
Avexis (AVXS)55.10.21 (0.38%)
Pfizer (PFE)34.260.2 (0.59%)
Abbvie (ABBV)62.090.15 (0.24%)
Eli Lilly (LLY)82.870.32 (0.39%)
Baxalta (BXLT)46.020.18 (0.39%)
Johnson & Johnson (JNJ)122.731.03 (0.85%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
Incyte (INCY)131.219.26 (7.59%)
Sarepta Therapeutics (SRPT)32.021.87 (6.2%)
Stemline Therapeutics (STML)6.850.4 (6.2%)
Bluebird Bio (BLUE)823.7 (4.73%)
Puma Biotech (PBYI)36.21.5 (4.32%)
Sangamo BioSciences (SGMO)40.15 (3.9%)
Epizyme (EPZM)12.150.45 (3.85%)
Top gainers from Medical-Biomed-Genetics industry
* As of Feb 25, 2017
CompanyPriceChange (%)
Achillion Pharma (ACHN)3.860.38 (8.96%)
Chromadex (CDXC)2.740.13 (4.53%)
Idera Pharma (IDRA)1.670.06 (3.47%)
Inovio Pharma (INO)6.680.22 (3.19%)
VIVUS (VVUS)1.140.03 (2.56%)
Ligand Pharma (LGND)100.382.46 (2.39%)
Compugen (CGEN)4.30.1 (2.27%)
Top losers from Medical-Biomed-Genetics industry
* As of Feb 25, 2017

Halozyme Therapeutics Financial Statements

income statement20152014201320122011
Net Sales Or Revenues135.05M75.33M54.79M42.32M56.08M
Net Income-32.23M-68.37M-83.47M-53.55M-19.76M
Total Operating Expense133.25M115.63M128.97M94.85M75.66M
view Halozyme Therapeutics, Inc. income statement
balance sheet20152014201320122011
Total Assets181.78M165.97M101.79M134.72M65.75M
Total Liabilities138.79M124.62M121.78M85.87M54.85M
Shareholders Equity42.99M41.35M-19.99M48.85M10.9M
view Halozyme Therapeutics, Inc. balance sheet
cash flow statement20152014201320122011
Net Increase (Decrease) In Assets Liabilities-29.49M0.1M22.1M-20.22M-21.24M
Net Cash From (Used By) Operating Activities-37.08M-47.51M-49.33M-64.32M-34.35M
Increase (Decrease) In Prop Plant And Equipment-2.36M-1.36M-2.29M-1.41M-0.82M
view Halozyme Therapeutics, Inc. cashflow statement

Halozyme Therapeutics, Inc. Stock News - Partner Headlines

Halozyme Therapeutics Stock Message Board

Halozyme Therapeutics stock lost 1.91 %, and the last close price as of 24 Feb, 2017 is 12.27 for HALO stock. Stock price or share price can be used to find the total market value of a company. Halozyme Therapeutics market cap stands at 1.56B as of 24 Feb, 2017. Halozyme Therapeutics valuation can be different from its intrinsic stock price when viewed from a value investors perspective.

The terms stocks and shares mean the same thing. For Ex: Halozyme Therapeutics stock price and Halozyme Therapeutics share price mean the same thing. The volume of shares traded stood at 1253648 on the last trading day, as is evident from Halozyme Therapeutics stock chart, and HALO stock quote data. A dividend is a cash payment from a company's earnings and is distributed among shareholders. Halozyme Therapeutics does not pay dividends. To check the historical stock price movement, all time high, and all time low of HALO, view Halozyme Therapeutics stock price history.